Key Developments: - **Guoxia Tech (02655)**: Opens IPO subscription from Dec 8–11, proposing a global offering of 33.85 million H shares with cornerstone investors like Wui Kai Hong. - **CStone Pharma-B (02616)**: Pralsetinib capsules (Gavreto®) included in China’s 2025 National Reimbursement Drug List (NRDL). - **Sihuan Pharma (00460)**: Innovative drug Xuan Yuening® added to NRDL for the first time. - **Shanghai Pharma (02607)**: Amisulpride orally disintegrating tablets successfully negotiated into NRDL. - **Hansoh Pharma (03692)**: Innovative drug Ameile® secures two additional indications in the 2025 NRDL update. - **Simcere Pharma (02096)**: Enzead® and Endostar® included in the updated NRDL. - **Hutchmed (00013)**: Tazverik® (tazemetostat) listed in China’s inaugural commercial health insurance innovative drug catalog. - **XuZhu Pharma-B (02575)**: Xuan Yuening® added to 2025 NRDL as a first-time inclusion. - **Innogen-B (02591)**: H shares now eligible for Stock Connect programs (Shanghai/Shenzhen). - **MCC (01618)**: Plans to sell non-core assets worth ~¥60.68B to focus on metallurgical engineering and mining operations. - **CIG (06166)**: To invest ¥405M in acquiring and subscribing to Yangzhong Happy Home Venture Capital Partnership fund shares.

Operational Performance: - **DONGFENG GROUP (00489)**: Jan–Nov vehicle sales fell 0.3% YoY to 1.697M units. - **CHINA SUNTIEN (00956)**: Jan–Nov power generation rose 8.04% YoY to 13.37M MWh. - **CHINA LONGYUAN (00916)**: Jan–Nov power generation edged up 0.41% YoY to 69.1M MWh. - **Powerlong Real Estate (01238)**: Jan–Nov contracted sales dropped 43.2% YoY to ¥6.67B.